首页> 外文期刊>Journal of applied microbiology >A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis
【24h】

A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis

机译:乳酸双歧杆菌,干酪乳杆菌和嗜酸乳杆菌三种益生菌在大鼠结肠炎TNBS模型中预防作用的比较研究

获取原文
获取原文并翻译 | 示例
       

摘要

The intestinal anti-inflammatory effects of three probiotics with immunomodulatory properties, Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium lactis, were evaluated and compared in the trinitrobenzenesulphonic acid (TNBS) model of rat colitis. Colitis was induced in rats by intracolonic administration of 10 mg of TNBS dissolved in 0p"25 ml of 50% ethanol. Each probiotic was administered orally (5 x 10i CFU suspended in 0p"5 ml of skimmed milk) for 3 weeks, starting 2 weeks before the administration of TNBS. Colonic damage was evaluated histologically and biochemically 1 week after TNBS instillation. The results obtained revealed that all probiotics assayed showed intestinal anti-inflammatory effects, macroscopically evidenced by a significant reduction in the colonic weight/length ratio. Only B. lactis showed a lower incidence of diarrhoea in comparison with untreated rats. Biochemically, all probiotics restored colonic glutathione levels, depleted as a consequence of the oxidative stress of the inflammatory process. Bifidobacterium lactis treatment reduced colonic tumour necrosis factor (TNF)-l production, and inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) expression; L. acidophilus administration reduced colonic leukotriene B production and iNOS expression and L. casei intake was associated with a decrease in colonic COX-2 expression. The three probiotics assayed have shown intestinal anti-inflammatory activity in the TNBS model of rat colitis, although each probiotic shows its own anti-inflammatory profile. These probiotics could be considered as potential adjuvants in the treatment of inflammatory bowel disease, although more studies are required in order to demonstrate their efficacy in humans.
机译:在大鼠结肠炎的三硝基苯磺酸(TNBS)模型中评估并比较了三种具有免疫调节特性的益生菌的肠道抗炎作用,它们分别是干酪乳杆菌,嗜酸乳杆菌和乳酸双歧杆菌。通过结肠内给药10 mg TNBS(溶于0p“ 25 ml 50%乙醇中)10 mg TNBS,在大鼠中诱发结肠炎。口服每种益生菌(5 x 10i CFU悬浮于0p” 5 ml脱脂牛奶中)3周,开始2 TNBS给药前数周。 TNBS滴注后1周,通过组织学和生化方法评估结肠损伤。获得的结果表明,所有测定的益生菌均显示出肠道抗炎作用,宏观上通过结肠重量/长度比的显着降低来证明。与未经治疗的大鼠相比,只有乳酸双歧杆菌显示出较低的腹泻发生率。从生化角度看,所有益生菌都能恢复结肠谷胱甘肽水平,这是由于炎症过程的氧化应激而耗尽的。乳酸双歧杆菌治疗减少了结肠肿瘤坏死因子(TNF)-1的产生,并诱导了一氧化氮合酶(iNOS)和环加氧酶2(COX-2)的表达;嗜酸乳杆菌的施用减少了结肠白三烯B的产生和iNOS的表达,干酪乳杆菌的摄入与结肠COX-2表达的减少有关。在大鼠结肠炎的TNBS模型中,测定的三种益生菌已显示出肠道抗炎活性,尽管每种益生菌均具有其自身的抗炎特性。这些益生菌可以被认为是治疗炎症性肠病的潜在佐剂,尽管需要更多的研究来证明其对人体的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号